Why 85% Stop GLP-1 Drugs (Denver Obesity Practice)
You’ve heard the success stories. Patients lose 15–20% of their body weight on GLP-1 medications. Life-changing results. But here’s the uncomfortable truth that nobody talks about at lunch: most of them don’t stay on these drugs.
The Real-World Data
A new retrospective cohort study published in JAMA Network Open analyzed 125,474 adults with overweight or obesity. The findings? Nearly 85% of patients without diabetes discontinued GLP-1 medications within two years.
That gap between clinical trial results and real-world dropout is no accident. It’s a feature of how we practice medicine—not a flaw in the drugs themselves.
Why Patients Stop
The study identifies four main culprits:
Gastrointestinal side effects remain the heavyweight champion of dropout reasons. Nausea, vomiting, and diarrhea aren’t myths. They’re real, they’re common in month one, and they’re the reason some patients flush their pens down the toilet. Yes, dose titration helps. No, it doesn’t work for everyone.
Age ≥65 carries higher risk. Older adults report more significant GI symptoms and often have competing health priorities. A 68-year-old on three blood pressure medications isn’t always eager to add a fourth drug, even if that drug melts weight.
Cost and access gaps are the invisible giant. Insurance coverage remains fragmented. Prior authorization delays treatment. Pharmacy logistics break continuity. The July 2026 Medicare bridge program will help (copay drops to $50/month), but for now, affordability is the elephant in the room.
Goal confusion shouldn’t surprise us. Some patients hit their target weight, feel great, and stop medication—not realizing these drugs require indefinite use to sustain their benefits. That’s on us as prescribers to explain clearly.
What This Means for Your Practice
Here in the Denver metro, we’re fortunate. Colorado ranks below the national obesity average. But that doesn’t mean our patients are immune to dropout.
The lesson is clear: dispensing a GLP-1 prescription isn’t the same as delivering obesity treatment. Long-term adherence demands proactive follow-up, side effect management, ongoing patient education, and honest conversations about the cost and commitment involved.
Patients don’t fail medications. Medications fail patients who aren’t adequately supported.
The Clinical Takeaway
GLP-1 medications are among the most effective obesity treatments we’ve ever had. They work. The real challenge—the one that separates good outcomes from mediocre ones—is keeping patients on them long enough to matter.
That’s where your clinical skill actually lies.
Source: JAMA Network Open (2026). Retrospective cohort analysis of 125,474 adults with overweight or obesity. hlth.com Insights